Nuvera, J&J's Veridex Ink Deal to Develop, Market Breast Cancer Drug Response Dx
April 08, 2009
Nuvera, J&J's Veridex Ink Deal to Develop, Market Breast Cancer Drug Response Dx
Terms of the deal call for Nuvera to run clinical trials to validate the assays, which gauge treatment response to tamoxifen and taxane-containing chemotherapies, and for Veridex to validate, launch, and market the tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Ignyta Buys Personalized Medicine Firm Actagene
May 21, 2013 / GenomeWeb Daily News - Genome Institute of Singapore, QuantuMDx Collaborate on Dx for Asia
May 21, 2013 / GenomeWeb Daily News - Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer
May 21, 2013 / GenomeWeb Daily News - Cancer Genetics Inks Deal with MultiPlan for Access to Tests, Services
May 21, 2013 / GenomeWeb Daily News - AB Sciex API 3200MD and 3200MD QTRAP Mass Specs Receive EU CE-IVDD Mark
May 20, 2013 / ProteoMonitor